GlassScriptPhysician profile
Charles H Futrell
NPI 1679751689
$4,158.50
in general payments reported to CMS, 2019-2025
35 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $305 · 2021: $410 · 2022: $257 · 2023: $629 · 2024: $956 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $693.95 | 2019-2025 | |
| Novo Nordisk INC | $567.29 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $409.86 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $300.99 | 2019-2025 | |
| Amarin Pharma, INC. | $234.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $216.32 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $212.99 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $194.24 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $144.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $120.72 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.70 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.12 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.94 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $83.89 | 2019-2020 | |
| Exact Sciences Corporation | $77.37 | 2024-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $71.63 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.37 | 2021-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $57.55 | 2019-2021 | |
| Tris Pharma INC | $39.80 | 2023-2024 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $33.05 | 2024-2025 | |
| Radius Health, INC. | $30.59 | 2023-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $28.42 | 2021 | |
| Axsome Therapeutics, INC. | $26.83 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $25.95 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Endogastric Solutions, INC | $25.11 | 2023-2024 | Esophyx |
| Supernus Pharmaceuticals, INC. | $24.76 | 2019-2020 | |
| Nevro Corp. | $19.55 | 2023 | Senza |
| Dexcom, INC. | $18.92 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $18.65 | 2021 | |
| Shire North American Group INC | $16.94 | 2019 | |
| Inspire Medical Systems, INC. | $15.87 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2020 | |
| Insulet Corporation | $14.20 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $12.99 | 2020 | |
| Sanofi Pasteur INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Futrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.